Examining the use of N-acetyl cysteine (NAC) for the prevention and treatment of HAAF
What is the Study about?
Low blood sugar is also called hypoglycemia. Usually, it is mild and can be treated quickly and easily by eating or drinking a small amount of a sugar-rich food. If low blood sugar is left untreated, it can get worse and cause confusion, clumsiness or fainting. Severe hypoglycemia can lead to seizures, coma, and even death.
Some people with diabetes do not have early warning signs of low blood sugar. This condition is called hypoglycemia unawareness. It happens when the body stops reacting to low blood sugar levels and the person does not realize that they need to treat their hypoglycemia. This can lead to more severe and dangerous hypoglycemia.
The purpose of this early study is to see if a drug called N-acetyl cysteine should be studied more in people with Type I diabetes and hypoglycemia unawareness, impaired awareness of hypoglycemia, or hypoglycemia associated autonomic failure (HAAF). This study will show whether N-acetyl cysteine (NAC) could be used to prevent and treat hypoglycemia unawareness.
Eligibility to participate
You may be eligible to participate in this Study if you:
- Are between the age of 18-65
- Have Type 1 diabetes
This study does not accept healthy participants.
This study is currently recruiting participants.
What is involved in the Study?
- 3 visits to the University of Minnesota Masonic Clinical Research Unit (MCRU)
- For 2 of the visits, spending 1 day and 2 nights at MCRU
- Receiving an IV solution of either N-acetyl cysteine (NAC) or saline
- Collection of blood samples at each visit